Step Pharma

Step pharma email format

Verified email-pattern data for Step Pharma is currently limited. You can still use the company insights and contact sections below.
Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and biomarker selection of patients. This can ultimately be viewed as a tumour agnostic approach with ovarian cancer being the PoC indication and future plans to expand into other tumour types such as NSCLC with high prevalence of the biomarker.

Company Details

Employees
14
Founded
-
Address
15, Rue Louis Et Auguste Lumière, Saint-Genis-Pouilly,auvergne-Rhône-Alpes 01630,france
Email
in****@****-ph.com
Industry
Biotechnology Research
Keywords
Wilmington.
HQ
Saint-Genis-Pouilly, Auvergne-Rhône-Alpes
Looking for a particular Step Pharma employee's phone or email?

Step Pharma Questions

Explore related pages

Related company profiles:

Top Step Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant